Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G.
Although intravenous immunoglobulin (IVIG) is highly effective in Kawasaki disease (KD), mechanisms are not understood and 10-20% of patients are treatment-resistant, manifesting a higher rate of coronary artery aneurysms. Murine models suggest that α2-6-linked sialic acid (α2-6Sia) content of IVIG...
Main Authors: | Shohei Ogata, Chisato Shimizu, Alessandra Franco, Ranim Touma, John T Kanegaye, Biswa P Choudhury, Natasha N Naidu, Yutaka Kanda, Long T Hoang, Martin L Hibberd, Adriana H Tremoulet, Ajit Varki, Jane C Burns |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3855660?pdf=render |
Similar Items
-
A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease.
by: Vered Padler-Karavani, et al.
Published: (2013-01-01) -
Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease
by: Khanh-Van Y. Van Anh, et al.
Published: (2020-04-01) -
Differential expression of miR-145 in children with Kawasaki disease.
by: Chisato Shimizu, et al.
Published: (2013-01-01) -
Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases
by: Yuliya V. Markina, et al.
Published: (2020-07-01) -
An Artificial Intelligence-guided signature reveals the shared host immune response in MIS-C and Kawasaki disease
by: Pradipta Ghosh, et al.
Published: (2022-05-01)